Literature DB >> 17533526

Resolution of acromegalic cardiomyopathy in mild acromegalic physical abnormality after short-term octreotide therapy.

Myung-Woo Hwang1, Akira Shimatsu, Yoshio Sasaki, Hiroyuki Ayukawa, Katsura Inenaga, Rei Takeoka, Tomoyuki Iwase, Chuichi Kawai.   

Abstract

Congestive heart failure developed in a 42-year-old man who had very mild acromegalic features. Echocardiography showed a marked dilatation of the left ventricle and decreased systolic function. Laboratory examinations revealed the elevated levels of growth hormone and insulin-like growth factor-1 and pituitary microadenoma was demonstrated by magnetic resonance imaging. Although the extensive conventional medical treatment was ineffective, short-term addition of somatostatin analog, octreotide, rapidly improved his cardiac function. After discontinuation of octreotide, further improvement was observed with minimal residual diastolic dysfunction. All medical treatment could be stopped after successful trans-sphenoidal surgery. Early diagnosis and effective treatment is important to reverse the acromegalic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17533526     DOI: 10.1007/s00380-006-0960-y

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  22 in total

1.  The somatotrophic system in patients with dilated cardiomyopathy: relation of insulin-like growth factor-1 and its alterations during growth hormone therapy to cardiac function.

Authors:  K J Osterziel; M B Ranke; O Strohm; R Dietz
Journal:  Clin Endocrinol (Oxf)       Date:  2000-07       Impact factor: 3.478

Review 2.  Acromegaly.

Authors:  S Melmed
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

3.  Histopathological improvement of acromegalic cardiomyopathy by intermittent subcutaneous infusion of octreotide.

Authors:  M Nishiki; Y Murakami; M Sohmiya; K Koshimura; K Inoue; Y Goto; N Nakamura; Y Kato
Journal:  Endocr J       Date:  1997-10       Impact factor: 2.349

4.  Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies.

Authors:  P Richardson; W McKenna; M Bristow; B Maisch; B Mautner; J O'Connell; E Olsen; G Thiene; J Goodwin; I Gyarfas; I Martin; P Nordet
Journal:  Circulation       Date:  1996-03-01       Impact factor: 29.690

5.  Dramatic improvement of severe dilated cardiomyopathy in an acromegalic patient after treatment with octreotide and trans-sphenoidal surgery.

Authors:  V Legrand; A Beckers; V T Pham; J C Demoulin; A Stevenaert
Journal:  Eur Heart J       Date:  1994-09       Impact factor: 29.983

6.  Cell death in acromegalic cardiomyopathy.

Authors:  A Frustaci; C Chimenti; M Setoguchi; S Guerra; S Corsello; F Crea; A Leri; J Kajstura; P Anversa; A Maseri
Journal:  Circulation       Date:  1999-03-23       Impact factor: 29.690

7.  Long-term outcome of patients with acromegaly and congestive heart failure.

Authors:  Hélène Bihan; Consuelo Espinosa; Hernan Valdes-Socin; Sylvie Salenave; Jacques Young; Suzanne Levasseur; Patrick Assayag; Albert Beckers; Philippe Chanson
Journal:  J Clin Endocrinol Metab       Date:  2004-11       Impact factor: 5.958

8.  The effects of octreotide in dilated cardiomyopathy: an open-label trial in 12 patients.

Authors:  Namlk Kemal Eryol; Muhammed Güven; Ramazan Topsakal; Murat Sungur; Ibrahim Ozdogru; Tugrul Inanç; Abdurrahman Oguzhan
Journal:  Jpn Heart J       Date:  2004-07

Review 9.  Acromegalic cardiomyopathy: a review of the literature.

Authors:  M P Matta; P Caron
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

10.  Research on cardiomyopathy in Japan.

Authors:  H Toshima
Journal:  Heart Vessels Suppl       Date:  1985
View more
  1 in total

1.  Face the truth: a 76-year-old man with chronic heart failure of unknown origin.

Authors:  Tomoharu Suzuki; Yasuharu Tokuda
Journal:  BMJ Case Rep       Date:  2014-05-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.